PRLD earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -3.70. Updated 2026-07-23.
Prelude Therapeutics (PRLD) Research Hub
Prelude Therapeutics (PRLD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.7 USD (+1.93%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.70, market cap 0.22B. This hub links to the full technical, earnings and options research available for PRLD.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.7 USD (+1.93%) |
| 52-week range | 3.18 USD – 6.82 USD |
| Trend regime | Range |
| 14-day RSI | 46.2 (Neutral) |
| Trailing P/E | -3.70 |
| Market cap | 0.22B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for PRLD
Covered Call on PRLD: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PRLD: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PRLD: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
PRLD technical analysis: range, last 3.7 USD, RSI 46.2, 52w range 3.18 USD–6.82 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PRLD in?
Prelude Therapeutics (PRLD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PRLD in an uptrend or downtrend?
As of 2026-10-26, PRLD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PRLD's trailing P/E ratio?
PRLD's trailing P/E is -3.70, with a market cap of 0.22B. See the earnings research page for full valuation detail.
When does PRLD next report earnings?
PRLD is next scheduled to report earnings on 2026-08-13.